Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo by Nicholas Kamm/AFP via Getty Images
The Trump administration may loosen intellectual property protections for some prescription drugs in order to win Democratic support for its new trade deal with Mexico and Canada, the Wall Street Journal reports.
The big picture: The protections are a big win for U.S. drug companies, as they would extend the length of time that biologics can reap the benefits of monopoly pricing in those two other countries.
Details: The original version of the new trade pact gave biologics 10 years of market exclusivity, but Democrats want this time period to be reduced.
- Right now, biologics have 12 years of market exclusivity in the U.S. They have only eight in Canada and five in Mexico, per The Globe and Mail.
- Generic drugmakers argue that 10 years may be too long once manufacturing biosimilars becomes more efficient.
Go deeper: